AgingResearch.NewsJoin free

Cognition Therapeutics

CompanyUnited States

Cognition Therapeutics develops one asset, in phase 3 (zervimesine in dementia with Lewy bodies). Mostly small molecule acting on proteostasis and TMEM97; based in the United States.

1
Asset
Furthest stage
Phase 3
6
Grants
0
Trials
2
Signals

Pipeline

1

  • zervimesine

    Antagonizes sigma-2 receptors to prevent toxic protein oligomers from binding to neurons.

    Phase 3, Small molecule, Proteostasis, TMEM97, dementia with Lewy bodies

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • People1
  • Signals2
  • Similar companies6

Intelligence